Meta-analyses showed both methadone and buprenorphine cut mortality risk in half compared to no treatment, marking a significant shift in Canadian guidelines that now recommend them as equal first-line options for opioid use disorder.
With violence rates reaching up to 87.5% globally, doctors face a 16 times higher risk of assault than other professionals—are safety measures keeping up in health care?
Intra-Cellular Therapies' breakthrough oral drug, lumateperone, has shown a remarkable 63% reduction in relapse risk for schizophrenia patients, offering hope for improved management of this pervasive condition.
Psychosis patients face up to 2.6 times higher mortality risk after prison release, with overdose and suicide leading the causes—highlighting critical gaps in post-release care.
A recent study investigates the impact of sexual trauma on mental health, revealing significantly elevated odds of schizophrenia, bipolar disorder, and major depressive disorder. #MentalHealthResearch